Arrakis Therapeutics Announces CEO Transition with Mark DeLong Appointed as New CEO Read More Jun 25, 2026
UCB completes acquisition of Candid Therapeutics, strengthening next generation immunology pipeline Read More Jun 17, 2026
Oak Hill Bio Raises $32.5 Million Series A Financing to Advance Antisense Oligonucleotide Therapy Rugonersen to Phase 3 Study in Angelman Syndrome Read More Jun 1, 2026
Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma Read More May 12, 2026
Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares Read More May 8, 2026
UCB to acquire Candid Therapeutics, building upon its existing immunology pipeline with novel T-cell engagers Read More May 3, 2026
